Thrombocythemia, Essential
Oncology·MeSH: Thrombocythemia, Essential
Prevalence
30.0 / 100K
1 drug in development·1 company·4 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| Bomedemstat | Merck & Co., Inc. (MRK) |
Frequently asked questions
How many drugs are in development for Thrombocythemia, Essential?
BioSniper tracks 1 drug in development for Thrombocythemia, Essential across 1 company.
How many clinical trials target Thrombocythemia, Essential?
There are 4 clinical trials targeting Thrombocythemia, Essential tracked by BioSniper.
What is the prevalence of Thrombocythemia, Essential?
The estimated prevalence of Thrombocythemia, Essential is approximately 30.0 per 100,000 population.
Deep-dive into Thrombocythemia, Essential
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis